Philips Launches Multicountry RADIQAL Trial for Ultra-low Radiation Coronary Procedures

Royal Philips has launched the RADIQAL (Radiation Dose and Image Quality Trial), a multicenter, randomized clinical study enrolling 824 coronary artery disease patients across hospitals in Spain, Czech Republic, Denmark, and the US. The trial aims to demonstrate that Philips' new ultra-low X-ray dose technology can reduce radiation exposure by 50% during coronary procedures without compromising image quality or procedural performance, addressing a key priority in interventional cardiology. The study also focuses on maintaining high-quality angiograms when using diluted contrast media in ultra-low contrast procedures. Philips' new technology, integrated into the Azurion image-guided therapy system, has received CE marking under the EU MDR regulatory framework but is not yet cleared in FDA-regulated markets, delaying US enrollment. The trial is expected to provide robust real-world evidence supporting patient and staff safety improvements, potentially enhancing Philips' competitive position in interventional cardiology. Principal investigators emphasize the importance of balancing radiation reduction with procedural efficacy, and the trial's outcomes could influence adoption and financial growth for Philips.